Replies to post #299034 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

I take Ashkan's statement as the assertion DCVax-L works in all populations. Clearly unproven, but it is a reasonable statement.

"Response" in this industry refers to a specific metric. Generally it is tumor shrinkage (RECIST, iRECIST, or such), but I can accept that somebody wants to define it differently in this space. But you have to define it. Then you have to measure it. And you use the same metric when comparing. Saying SOC has a 25% RR via RECIST while DCVax has a 85% (or is at 110%?) based on increased cytokine production is total garbage.

I have never seen any metric published that would support LG's assertion and has any known clinical meaning. Maybe there is. but nobody knows it.